What happened
FDA states that its April 27 to May 1, 2026 inspection of SnugZ USA’s OTC drug manufacturing facility identified significant CGMP violations. The firm routinely failed to investigate out-of-specification chemical and microbiological results, instead retesting or preparing new samples until passing results were obtained and using those results for product release. Complaint investigations lacked adequate root cause determinations and CAPA. Laboratory procedures permitted repeated testing without investigations and allowed analysts discretion regarding unidentified chromatographic peaks. FDA also found unsupported tiered microbiological testing, with failing results invalidated in favor of passing results from a second instrument. Incoming components were not adequately identity-tested or representatively sampled, and supplier certificates of analysis were accepted without establishing their reliability through confirmatory testing. FDA further states that the quality unit did not adequately oversee manufacturing, testing, records, investigations, release decisions, cleaning validation, or product quality reviews. Similar investigation and laboratory-control deficiencies had been observed previously, and FDA considered the firm’s remediation responses insufficiently detailed and sustainable.
Why it matters
FDA states that passing retests alone cannot invalidate OOS results and that unreliable or incomplete testing data compromise the quality unit’s ability to ensure compliance with applicable standards. Unsupported release decisions may therefore fail to identify chemical, microbiological, or manufacturing problems affecting product quality. Inadequate incoming-material testing also leaves the firm without scientific evidence that components meet specifications before use. The repeated findings and deficient quality oversight indicate broad weaknesses across laboratory controls, investigations, CAPA, supplier qualification, and batch-release governance.
Key topics: Repeated invalidation of OOS chemical and microbiological results through unjustified retesting, Inadequate component identity testing and unsupported reliance on supplier certificates of analysis, Quality unit failure to oversee records, investigations, cleaning validation, and product release